India developed the Feluda test, which uses Crispr gene-editing technology to detect CoVid-19. Scientists estimate it will show results in under an hour and cost about 500 rupees or 9.52 AUD.
Researchers at the Delhi based CSIR-Institute of Genomics and Integrative Biology, tested the kit on samples from 2,000 patients, including on CoVid-19 positive patients.
They found the new test had 96% sensitivity and 98% specificity. This means almost everyone with the disease can be detected, while ensuring the least amount of false negatives.
Feluda, made by Indian conglomerate Tata, cleared the test for commercial use by drug regulators as India confirms over 6 million infections.